2seventy bio, Inc. entered into share purchase agreement for private placement of 1,114,827 common shares at a price of $17.94 per share for gross proceeds of $19,999,996.38 on January 6, 2023. The transaction included participation from new investor, Regeneron Pharmaceuticals, Inc. The par value of shares is $0.0001 per share. The shares are issued at a premium of 50%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.915 USD | +0.10% |
|
+24.62% | +14.99% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,093 USD | -0.16% | +3.89% | 118B | ||
4.915 USD | +0.10% | +24.62% | 252M | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.99% | 252M | |
+25.83% | 47.96B | |
+0.69% | 42.45B | |
+44.30% | 41.47B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- TSVT Stock
- News 2seventy bio, Inc.
- 2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.